ARS Pharmaceuticals Inc
For the period ended Sep 30, 2024. Filed Nov 13, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 13, 2024
SPRY$3.57+13.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(in thousands)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities: | ||
| Net loss | $(41,936) | $(47,197) |
| Non-cash adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 10,271 | 6,957 |
| Depreciation | 50 | 61 |
| Amortization and accretion, net | (5,710) | (5,121) |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | (773) | — |
| Inventories | (183) | — |
| Prepaid and other assets | 1,060 | 481 |
| Donation of equipment | 30 | — |
| Accounts payable and accrued liabilities (including related party amounts of $(45) and $192, respectively) | 8,749 | 6,104 |
| Operating right-of-use assets and lease liabilities, net | (14) | (9) |
| Contract liability | — | (3,137) |
| Net cash used in operating activities | (28,456) | (41,861) |
| Cash flows from investing activities: | ||
| Purchases of short-term investments, available-for-sale | (192,580) | (237,953) |
| Maturities of short-term investments, available-for-sale | 191,000 | 125,000 |
| Payments of milestone obligations under license agreements | (2,500) | — |
| Purchase of property and equipment | (261) | (266) |
| Net cash used in investing activities | (4,341) | (113,219) |
| Cash flows from financing activities: | ||
| Proceeds from exercise of common stock options and employee stock purchase plan | 1,483 | 5,094 |
| Net cash provided by financing activities | 1,483 | 5,094 |
| Net change in cash and cash equivalents | (31,314) | (149,986) |
| Cash and cash equivalents at beginning of period | 70,971 | 210,518 |
| Cash and cash equivalents at end of period | $39,657 | $60,532 |
| Supplemental cash flow information: | ||
| Intangible assets included in accounts payable | $5,000 | $— |
| Stock-based compensation capitalized into inventory | $110 | $— |
| Prepayment included in accrued expenses | $110 | $— |
| Purchases of inventories included in accounts payable | $422 | $— |
| Purchases of property and equipment included in accounts payable | $87 | $91 |
| Purchases of property and equipment reclassed from prepaid expenses and other current assets | $— | $174 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.